

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10569873	
	Filing Date		2007-09-04	
	First Named Inventor	Wei Cheng		
	Art Unit	1626		
	Examiner Name	TBD		
	Attorney Docket Number	05-953-A5		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
/K.B./	1	2005/016870	WO	A	2005-02-24	Smithkline Beecham Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10569873
Filing Date	2007-09-04
First Named Inventor	Wei Cheng
Art Unit	1626
Examiner Name	TBD
Attorney Docket Number	05-953-A5

/K.B./ ↓ ↓ ↓ ↓ ↓	1	ASHTON, W. et al., "Irreversible Enzyme Inhibitors. 198. Diaminodihydro-s-triazines and diaminopyrimidines bearing substituted (ureidomethyl)phenyl substituents as reversible inhibitors of dihydrofolate reductase", Journal of Medicinal Chemistry, 16(5), 453-6.	<input type="checkbox"/>
	2	AUZOU, G. et al., "2,5-Dimethylpyrroles as analgesics", STN Database Accession No. 1985:89665, Chemical Abstracts Service, Columbus, Ohio, 1 page, XP002486521.	<input type="checkbox"/>
	3	Database Accession No. 8640850, Database Crossfire Beilstein, Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften, Frankfurt AM Main, 1 page, XP002486522.	<input type="checkbox"/>
	4	Database Accession No. 1495354, Database Crossfire Beilstein, Beilstein Institut Zur Foerderung Der Chemischen Wissenschaften, Frankfurt AM Main, 1 page, XP002486523.	<input type="checkbox"/>
	5	SOLIMAN, R. et al., "Preparation antidiabetic activity of new 3-methyl-5-phenylpyrazolesulfonylurea derivatives", Journal of Phamaceutical Sciences, 70(6), 602-605.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Kristin Bianchi/	Date Considered	04/22/2009
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.